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Abstract
Beyond cancer-cell intrinsic factors, the immune status of the host has a prognostic impact on patients with
cancer and influences the effects of conventional chemotherapies. Metastatic melanoma is intrinsically
immunogenic, thereby facilitating the search for immune biomarkers of clinical responses to cytotoxic agents.
Here, we show that a multi-tyrosine kinase inhibitor, sorafenib, upregulates interleukin (IL)-15Ra in vitro and in
vivo in patients with melanoma, and in conjunction with natural killer (NK) group 2D (NKG2D) ligands,
contributes to the Th1 polarization and accumulation of peripheral CD4þNKG2Dþ T cells. Hence, the increase of
blood CD4þNKG2Dþ T cells after two cycles of sorafenib (combined with temozolomide) was associated with
prolonged survival in a prospective phase I/II trial enrolling 63 patients with metastatic melanoma who did not
receive vemurafenib nor immune checkpoint–blocking antibodies. In contrast, in metastatic melanoma patients
treated with classical treatment modalities, this CD4þNKG2Dþ subset failed to correlate with prognosis. These
findings indicate that sorafenib may be used as an "adjuvant" molecule capable of inducing or restoring IL-15Ra/
IL-15 in tumors expressingMHC class I–related chain A/B (MICA/B) and on circulatingmonocytes of responding
patients, hereby contributing to the bioactivity of NKG2Dþ Th1 cells. Cancer Res; 74(1); 68–80. 2013 AACR.
Introduction
Therapy for metastatic melanoma remained unsatisfactory
for many decades. A range of various treatment modalities
based on chemotherapy has had little impact on survival (1). As
a single agent, dacarbazine (DTIC) has been commonly used
(2). Some investigators substitute DTIC with temozolomide
(related oral alkylating agent) for its convenience of adminis-
tration and its central nervous system penetration. A phase III
trial comparing an extended schedule of temozolomide with a
standard dose of single-agent DTIC failed, however, to show
any statistical differences in terms of response rates, progres-
sion-free survival, and overall survival (OS; refs. 3, 4). Temo-
zolomide produces response rates of 4.13% and a median
progression-free survival of 1.9 months in patients without
brain metastases. More recently, advances in understanding
the genetic changes associated with melanoma development
identified activatingmutations in the serine/threonine kinases
BRAF (5), establishing mitogen-activated protein kinase sig-
naling pathways as new drug targets inmelanoma. Sorafenib, a
multikinase inhibitor of VEGF receptor (VEGFR), KIT, plate-
let—derived growth factor receptor (PDGFR), and RAF pro-
teins as well as several proangiogenic tyrosine kinases, was
tested in phase II trials alone or in combination with carbo-
platin and paclitaxel and seemed to be promising on response
rates andmedian progression-free survival, but was associated
with toxicity (6). Unfortunately, subsequent phase III trials of
the combination of sorafenib and paclitaxel/carboplatin only
demonstrated benefit in patients withmetastaticmelanoma in
first and second line of therapy (7, 8). Next, even before the era
of more specific BRAF inhibitors, Amaravadi and colleagues
conducted a phase II trial combining temozolomide with
sorafenib in advanced melanoma, showing relative safety and
activity in patients without prior history of temozolomide (9).
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In parallel, attempts to harness antitumor immunity have
progressively led to therapeutic success in melanoma (10).
Anti-CTLA-4 antibodies alone or together with peptide-based
vaccination or with DTIC significantly prolonged survival of
stage III/IV melanoma in two phase III trials (10, 11). One
surmises that in patients responding to immunotherapy,
tumor- and/or vaccine-specific T cells reset local tumormicro-
environment and convert immune tolerance into immune-
related tumor destruction (12).
Because vaccines showed some unexpected efficacy after
tumor progression with cytotoxic compounds (13, 14), a new
concept emerged whereby the host immune system could
contribute to the beneficial effects of cytotoxic compounds
(15). Indeed, the outcome of chemotherapy can be influenced
by the host immune system at multiple levels. Chemotherapy
can kill cancer cells in a way that they elicit an immune
response (16) or, alternatively, increase their susceptibility to
immune attack (17). In addition, chemotherapy can stimulate
anticancer immune effectors either directly (by activating
effector or dendritic cells) or indirectly by subverting immu-
nosuppressive mechanisms (18, 19). Hence, a recent report
pointed out that patients with metastatic melanoma respond-
ing toDTIC exhibit a stromal and immune signature, definedby
hallmarks of T-cell infiltration andMHCclass II expression (20).
A number of immune effectors, including dendritic cells, T
cells, and natural killer (NK) cells, have been involved in natural
or therapy-induced tumor immunosurveillance in mice (21,
22). The NK group 2D (NKG2D), a lectin-like activating recep-
tor, markedly influences IFN-g release and cytotoxic responses
upon tumor recognition, exerting selective pressure on trans-
formed cells (23). A large body of preclinical work highlighted
the beneficial role of the activating receptor NKG2D in immu-
nosurveillance against cancer (24, 25). In most instances,
NKG2D-induced effects are mediated through NK or CD8þ
effector T cells. Here, we unveil the immunomodulatory role of
a multi-tyrosine kinase inhibitor, sorafenib, on a rare subset of
circulating (and intratumoral) CD4þCD8dimNKG2Dþ T cells
prone to secrete Th1 cytokines upon cotriggering of CD122 (IL-
2/IL-15Rb chain) and NKG2D receptors. Indeed, sorafenib
induced the upregulation of interleukin (IL)-15Ra expression
on tumor cells in vitro and in vivo, and/or on circulating
monocytes in metastatic melanoma (cotreated with temozo-
lomide) in a phase I/II prospective trial. In all patients with
metastatic melanoma, melanoma expressed high intrinsic
levels of MHC class I–related chain A/B (MICA/B) molecules.
Patients developing enhanced frequencies of CD4þNKG2Dþ T
cells after two cycles of sorafenib exhibited prolonged survival.
Of note, such CD4þNKG2Dþ T cells failed to dictate the
prognosis in another cohort of metastatic melanoma enrolled
in a MAGE3 protein (26) underscoring the immunoregulatory
role of sorafenib.
Materials and Methods
Patients and treatment plan
SORAFTEM. Sixty-three patients older than 18 years of
age, with histologically confirmed metastatic or unresectable
melanoma,measurable disease, an Eastern Cooperative Oncol-
ogy Group performance status less than 2, with adequate
hematologic, renal, hepatic, and coagulopathic functions, were
included in a phase I/II investigator-sponsored study SORAF-
TEM (European Union Drug Regulating Authorities clinical
trial EudraCT 2007-000527-18). The number of prior therapies
is summarized in Table 1. Patients had discontinued their
earlier systemic therapy at least 4 weeks before entering the
trial. Previous brain radiotherapy was allowed, provided
patients were not clinically symptomatic. The study protocol
Table 1. Characteristics of patients (n ¼ 63)
Gender (male/female) 35/28
Age (mean  SD) [range] 48.5  13.8 [22–75]
Type
SSM 20
Nodular 12
Lentigo maligna 1
Acral lentiginous 2
Mucosal 7
Ocular 4
Other 17
Metastasis (56 patients
have metastases)
Number of metastasis lesions
per patient (mean  SD)
5.1  2.0 [1–10]
Metastatic sites
Nodes 40
Liver 11
Lung 22
Peritoneum 8
Skin 19
Bone 7
Muscle 4
LDH level U/L (mean  SD)
[range]
341  478 [90–3,500]
LDH  250 U/L 34
LDH > 250 U/L 23
ND 6
Treatment schedule
sorafenib 400 mg/d,
temozolomide 100 mg/m2
3
sorafenib 400 mg/d,
temozolomide 150 mg/m2
6
sorafenib 800 mg/d,
temozolomide 150 mg/m2
54
Previous chemotherapy
No 9
One line 22
Two lines 19
Three lines 10
Four lines 3
3-month evaluation
Responders 26
Nonresponders 37
Abbreviations: SSM, spreading superficial melanoma; ND,
not determined.
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was approved by the Institutional Review Boards at the Uni-
versity of Kremlin Bice^tre (Paris, France) and Institut Gustave
Roussy (Villejuif, France). All patients provided informed con-
sent before enrollment. The treatment plan is outlined in
Supplementary Fig. S1. Stage III and IV melanoma-bearing
patients were enrolled from 2006 to 2009 in a dose-escalating
phase I followed by a phase II extension cohort at the max-
imum-tolerated dose trial testing the efficacy of the combina-
torial regimen of temozolomide (Schering Plough; 100–150
mg/m2 daily for 7 days every 2 weeks) and sorafenib (Bayer;
400–800 mg twice daily without interruption). Therapy was
continued until disease progression or intolerable toxicity.
Response assessments consisted of physical examination every
4 weeks together with computed tomography scans of the
chest, abdomen, and pelvis every 8 weeks. Patients were
assessed by an investigator using the Response Evaluation
Criteria in Solid Tumors (RECIST) guidelines 1.1. Responses
were confirmed by follow-up radiographic evaluation 4 weeks
after the initial response criteria were met. BRAF mutations
were determined according to technical methods previously
described (9). The primary endpoint of the trial was the efficacy
of the treatment at 3 months. Patients were classified as
objective response or stabilization (called "responders" hence-
forth) versus progressive disease or death (PD; called "non-
responders" henceforth).
MAGE3 protein–based vaccines. The details about
patient characteristics, protocol description, and survival have
been previously reported by Kruit and colleagues (26). CD4þ
NKG2Dþ T cells were analyzed at in the beginning before
vaccine inoculation (1 month after relapse with conventional
therapies) and correlated with OS.
NY-ESO-1 vaccine trial. Prevaccine peripheral blood sam-
ples were collected from patients with malignant melanoma,
sarcoma, breast, and ovarian cancer enrolled in a clinical trial
of vaccination with recombinant NY-ESO-1, Montanide ISA 51,
and CpG 7909 (27) upon informed consent and approval by the
Institutional Review Board of Columbia University Medical
Center (New York, NY).
Immunohistochemistry studies
Paraffin-embedded tumor tissues were first rehydrated and
then treated with hydrogen peroxide (H2O2; DAKO) for neu-
tralizing endogenous peroxidase and SerumFree Protein Block
(DAKO) to prevent nonspecific binding. After blocking, pri-
mary antibody, anti-MICA/B (SR99; a kind gift from Sophie
Caillat-Zucman, INSERM, U1016, Saint Vincent de Paul Hos-
pital, Paris, France) was applied. Binding specificity was con-
trolled by immunoglobulin G (IgG)1-isotype controls (RnD).
For visualization, EnVision anti-mouse (DAKO) horseradish
peroxidase–conjugated streptavidin was applied, followed by
the chromogen 3,30-diaminobenzidine/H2O2 (DAB; DAKO).
Immunostained sections were counterstained very briefly with
Mayer's Hemalaun, dehydrated, and clearedwith xylene, before
covered with mounting medium (toluene-based) and cover-
slips (DAKO). For staining of anti-CD3 (polyclonal rabbit, 1:150;
DAKO), anti-CD4 (1:20; Novocastra), and anti-CD8 (1:25; Novo-
castra), the Benchmark system was used. For detection of IL-
15Ra, primary antibody (AF247; R&D Systems) was applied at
10 mg/mL after blocking, and anti-goat IgG Alexa Fluor 568 was
used at 5 mg/mL as secondary antibody. Isotype-matched
antibody was used as negative controls. Samples were
mounted in ProLong Gold antifade with 40,6-diamidino-2-
phenylindole (DAPI) reagent (Molecular Probes). Fluorescent
images were analyzed with an epifluorescent microscope
(Zeiss Apotome Microscope).
PBMC preparations
Blood samples were drawn from 63 patients before and after
each treatment cycle and from12healthy volunteers. Peripheral
blood mononuclear cells (PBMC) were resuspended in culture
medium, i.e., RPMI-1640 (GIBCO Invitrogen), 10% human ABþ
serum (Jacques Boy), 1% penicillin/streptavidin (PEST; GIBCO
Invitrogen), and 1% 2 mmol/L glutamine (GIBCO Invitrogen).
Some cells were then stained for flow-cytometric analyses and
the rest were resuspended in CryoMaxx medium (PAA Labo-
ratories) for storage in liquid nitrogen.
Tumor-infiltrating lymphocytes preparations
Resected lymph node specimens and/or metastatic tissue
from 16 patients with metastatic melanoma were analyzed for
infiltrating lymphocytes. Tissue samples were placed in dis-
sociation medium, i.e., RPMI-1640, 1% PEST, collagenase IV
(8,000 UI/mL), hyaluronidase (112,000 IU/mL), and DNAse
(12,700 IU/mL), and run on a gentleMACS dissociator (Mil-
tenyi Biotec). The cell samples were then diluted in RPMI-
1640þ 10% human ABþ serum, passed through a cell strainer,
and centrifuged for 10 minutes at 300 g. Next, the cells were
resuspended in PBS and stained for flow-cytometric analyses.
Tumor-coupled specimens of noninvaded lymph node or
blood samples were obtained from 10 patients and were
analyzed as above.
Flow cytometry
Cells were stained with fluorochrome-coupled monoclonal
antibodies (mAb), incubated for 20 minutes at 4C, and
washed. Adherent cells were treated with trypsine (Gibco)
before the staining step. Cell samples were analyzed using a
CyAn ADP 9-Color flow cytometer (Beckman Coulter) or an
LSRII flow cytometer (BD Biosciences). For proper compen-
sation, single-stained antibody-capturing beads were used
(CompBeads; BD Biosciences). Data were analyzed using
FlowJo (TreeStar, Inc.) or FACSDiva (BD Biosciences). For
accurate determination of nondiscrete populations, fluores-
cence-minus-one (FMO) controls were used. For dead-cell
discrimination, DAPI (Invitrogen) or thefixable amine-reactive
LIVE/DEAD Cell-Stain Kit (Invitrogen) was used. For pheno-
typic analysis of CD4þNKG2Dþ T cells, PBMC samples from 11
patients were thawed and resuspended in PBS for 9-color flow-
cytometry staining. T cells of interest were identified by CD3,
CD4, CD56, CD8, CD14, and NKG2D mAbs and costained with
CD28 andCD45RA, or 2B4 andCD161, or IL-15Ra andCX3CR1,
or CD25 and CD158 antibodies. The following fluorochrome-
coupled anti-human mAbs were used: anti-CD3 (Miltenyi
Biotec, BD, Beckman Coulter), anti-CD4 (BD), anti-CD8 (BD,
eBioscience), anti-CD14 (BD, eBioscience), anti-CD56 (Beck-
man Coulter), anti-NKG2D (Miltenyi Biotec), anti-Foxp3
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(eBioscience), anti-CD25 (BD), anti-CD28 (BD), anti-CD45RA
(BD, eBioscience), anti-2B4 (BD), anti-CD161 (Beckman Coul-
ter), CD158a (BD), anti-CX3CR1 (MBL), and anti-Ki67 (BD).
Rabbit polyclonal anti-IL-15Ra IgG antibody was purchased
fromSantaCruzBiotechnology. Purifiedanti-CD3 (OKT3), anti-
NKG2D (AF750), and goat anti-rabbit IgG-allophycocyanin
(APC) were purchased from BioLegend.
T-cell purification and functional assays
Frozen PBMC samples were quickly thawed, washed, and
resuspended in recommendedmedium (RoboSepBuffer; STEM-
CELL Technologies) for magnetic bead separation with the
EasySep Human CD4-Positive Selection kit (STEMCELL Tech-
nologies). Positive-selection kit was chosen to avoid depleting
CD8þ CD4þNKG2Dþ T cells. For isolation of CD4þNKG2Dþ T
cells and NKG2Dþ NK cells, previously frozen PBMCs were
stained with mAbs to CD3, CD4, CD56, CD14, and NKG2D and
sorted by flow cytometry on a three-laser MoFlo XDP cell sorter
(Beckman Coulter), or a three-laser ARIA III cell sorter (BD).
More than 98% pure populations of CD3þ/CD4þ/NKG2Dþ/
CD56/CD14 and CD56þ/NKG2Dþ/CD3/CD4/CD14 cells
were obtained.
Cytokine production. PBMCs from patients with meta-
static melanoma were thawed and resuspended in culture
medium, and kept at 37C, overnight. The next day, cells were
enriched for CD4þ T cells and seeded at 106 cells/mL on a flat-
bottomed Nunc MaxiSorp 96-well plate, precoated with or
without anti-CD3 antibody (0.5 mg/mL), anti-CD122 antibody
(1, 10 mg/mL), and anti-NKG2D antibody (4 mg/mL) alone or in
combination. After 20 hours of cell culture, the supernatant
was collected, cleared by centrifugation, and analyzed byELISA
for quantification of IFN-g (BD), IL-2 (BD), TNF-a (BD), IL-17
(R&D Systems), and IL-10 (BD) according to the instruction
manuals. For cytokine-release from purified cells, fluores-
cence-activated cell sorting (FACS)-sorted CD4þNKG2Dþ T
cells and NK cells were cultured overnight in the presence or
absence of soluble MIC (sMICA; 5 ng/mL; a kind gift from
Sophie Caillat-Zucman) and recombinant IL-15 (rhIL-15;
5 ng/mL; R&D Systems) alone or in combination. Release of
IFN-g into the supernatant was then measured by ELISA
according to the manufacturer's instructions.
Proliferation. After precoating UV-sterilized MaxiSorp
Nunc plates with or without anti-CD3 antibody (1 mg/mL),
we plated CD4þ T cells in the presence or absence of sMICA
(5 ng/mL) and IL-15 (5 ng/mL) alone or in combination. Cells
were then cultured for 5 days, and then harvested for staining
with the phycoerythrin (PE)-coupled Ki67, as well as other
surface mAbs.
Cytotoxicity. PBMCswere cultured in RPMI/10%SABwith
or without 20 ng/mL IL-15 for 4 days. One day before coculture,
MEL10 target cells were stained with CMTMR (Invitrogen),
seeded on a round-bottomed plate (10,000 cells/well), and
treated with or without sorafenib (10 mmol/L). The next day,
PBMCs were collected and enriched for CD4 cells before
FACSAria III-sorting of NKG2D-positive/negative cells. Target
cells were washed with PBS before adding 40,000 sorted T cells
to each well and cultured for 20 hours. Floating cells were then
transferred to FACS tubes and adherent cells were trypsinized
and collected into the same tubes. After centrifugation, the
cells were resuspended in PBS and analyzed on a FACSCanto
II (BD). For cell death determination, To-Pro-3 (Invitrogen)
was added to the tube just before running.
Exposure of melanoma cells to cytotoxic compounds
Eight human melanoma cell lines, M14, M96, MELP, MEL8,
MEL397, MEL888, MT10, and MZ2 were plated and grown
confluent in Dulbecco's Modified Eagle Medium (DMEM)
medium (GIBCO Invitrogen) supplemented with 10% FBS
(PAA Laboratories), and 1% PEST. Cells were then cultured
in the presence or absence of sorafenib (5 mmol/L, Nexavar;
Bayer) and temozolomide (50 mmol/L, Temodal; Schering
Plough) alone or in combination (protocol without cell death,
not shown). The next day, cells were collected and labeled with
IL-15Ra polyclonal antibody (H107) followed by an APC-cou-
pled secondary antibody and then stained with DAPI for dead-
cell exclusion for flow cytometry analysis. FMO tubewas added
as negative control, and background staining was excluded
with a goat anti-rabbit IgG-APC.
Quantitative reverse transcription PCR for IL-15Ra
isoforms
Total cellular RNA was isolated from melanoma cells with
the RNeasy Kit (Qiagen). First-strand cDNA was synthesized
from 1 mg of total RNA using SuperScript III Reverse Tran-
scriptase (Life Technologies) and randomprimers according to
themanufacturer's instructions. The quantitative reverse tran-
scription PCR (qRT-PCR) for IL-15Ra (Hs00542604_m1,
Hs01986843_m1, and Hs00233692_m1) isoforms and for b2-
microglobulin was performed by real-time fluorescence mea-
surement using StepOnePlus System (Life Technologies). The
qRT-PCR data were adjusted to b2-microglobulin measure-
ments using the 2DCT method (28).
Microarray
Global gene expression analysis was performed on 20 cDNA
samples frombiopsies of patientswithmelanomaprior andpost
two cycles of sorafenib/temozolomide, using the Human Gene
Expression 8 60 K Agilent Human Microarray Kit. Functional
analysis was carried out through the Ingenuity PathwayAnalysis
(Ingenuity System).
Statistical analyses
Differences between groups of quantitative data were
assessed by Mann–Whitney U test or Wilcoxon signed-rank
test for all distributions, or Student paired or unpaired t test if
the criteria for Gaussian distribution was met. All reported P
values were two-sided, and a P value of less than 0.05 was
considered statistically significant.
Results
Effector memory CD4þNKG2Dþ T cells in metastatic
melanoma patients
In accordance with a previous report (9), the sorafenib and
temozolomide combination therapy (schedule summarized in
Supplementary Fig. S1) induced one complete response (CR),
four partial responses (PR), and 21 disease stabilizations (SD)
Sorafenib Regulates IL-15Ra and NKG2D Ligands
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Figure 1. Increase of CD4þNKG2Dþ T cells exhibiting an TEM phenotype. A, flow cytometry analyses of NKG2D expression on freshly isolated subsets of
circulating lymphocytes [CD3þCD8þ (left), CD3CD56þ (middle), and CD3þCD4þ (right)] in metastatic melanoma before (0) and after one to two
cycles (1, 2) of therapy as well as in sex- and age-matched healthy volunteers (HV). Each dot represents 1 patient or healthy volunteer. Intraindividual
variations between pre- and posttherapy are analyzed by paired Student t test (, P < 0.05; , P < 0.01). B, flow cytometry analyses of NKG2D
expression according to CD4 and CD8 expression. NKG2D expression on CD4þ T cells proportional to the staining with anti-CD8 mAb shown in a
representative histogram (right). C and D, phenotyping of CD4þNKG2Dþ T cells recovered from metastatic melanoma at diagnosis according to
CD45RA and CCR7 expression (C) or from 11 patients with metastatic melanoma in a kinetic study according to various NK cell receptors (D). Student t
test to compare CD4þNKG2Dþ or NKG2D T cells; , P < 0.001. Intraindividual variations between pre- and posttherapy are analyzed by
Wilcoxon signed-rank test (ns, not significant).
Romero et al.
Cancer Res; 74(1) January 1, 2014 Cancer Research72
on January 23, 2020. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 6, 2013; DOI: 10.1158/0008-5472.CAN-13-1186 
IFN-g
500
400
300
200
100
0
*
Co
nt
ro
l
aC
D3
aN
K
G
2D
aC
D3
 +
aN
K
G
2D
pg
/m
L
A
C
IFN-g
TN
F-
a
IFN-g
TN
F-
a
CD4
N
K
G
2D
12%
1.5%
CD4 T cells
NKG2D+ cells
NKG2D– cells
B
IL-2
100
80
60
40
20
0
pg
/m
L
Co
nt
ro
l
aC
D3
aN
K
G
2D
aC
D3
 +
aN
K
G
2D
*
TNF-a
160
140
120
100
20
0
80
60
40
pg
/m
L
Co
nt
ro
l
aC
D3
aN
K
G
2D
aC
D3
 +
aN
K
G
2D
*
%
 IF
N-
g–
po
si
tiv
e 
ce
lls
 
0
1
2
3
4
0 1 10 0 1 10
Ctrl aNKG2D aCD3 aNKG2D+aCD3
aCD122:
(mg/mL)
NKG2D– 
CD4 T cells
NKG2D+ 
CD4 T cells
Figure 3. Synergistic effects of TCR, CD122, and NKG2D engagement for
Th1polarization inCD4þNKG2DþTcells. A, TCRandNKG2D-dependent
Th1 cytokine release by CD4þNKG2Dþ T cells. Cytokine release was
measured using ELISA for human IFN-g , IL-2, and TNF-a in the
supernatants of circulating CD4þ T cells recovered before therapy in 4
patients with metastatic melanoma. Cells were stimulated overnight with
a combination of suboptimal amounts of anti-CD3 (aCD3; 0.5 mg/mL) and
anti-NKG2D (aNKG2D; 4 mg/mL) antibodies. IL-17 and IL-10 were not
detectable in these conditions (not shown). The graph depicts the means
þ SEM of cytokine release from four metastatic melanoma (each one
being tested in triplicate wells). The synergistic effect of aCD3 + aNKG2D
was tested by Student t test (, P < 0.05). B, cytokine production, gating
on CD4þNKG2Dþ (top) and CD4þNKG2D (bottom) at 48 hours of
stimulation using flow cytometry and intracellular stainings. A
representative dot plot is depicted. C, the synergistic effect of CD122
triggering (dose response of cross-linked anti-CD122 agonistic antibody)
together with TCR/NKG2D engagement on cell-sorted CD4þNKG2Dþ or
NKG2D T cells from 3 patients with metastatic melanoma. Data from
one representative patient show the percentage of IFN-gþ cells assessed
by flow cytometry and intracellular staining.
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Figure 2. Phenotype of CD4þNKG2Dþ tumor-infiltrating lymphocytes in
metastatic melanoma. A, flow cytometry analyses of CD45þCD3þCD4þ
infiltrating lymphocytes in blood, noninvaded lymph node (Non-met LN),
lymph node metastasis (Met LN), or other metastatic tissue (Met). A
representative dot plot is shown with the percentages of NKG2Dþ cells
among the CD4þ T-cell population (left two). In 9 cases, paired specimen
[coupling blood or noninvaded lymph node to tumor beds (Met lymph
node or Met)] were examined (connected lines, right). Wilcoxon signed-
rank test showed no statistical significance (ns). B and C, expression of
PD-1 and Tim-3 on CD45þCD3þCD4þ tumor-infiltrating lymphocytes
(Met LN) versus PBMCs (Blood) based on NKG2D expression.
A representative dot plot (B) is shown and the results from 9 Met lymph
nodes are depicted in the graph (C). Student t test was used to compare
CD4þNKG2Dþ and NKG2D T cells; , P < 0.05; ns, not significant.
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Figure 4. Sorafenib-induced cell surface expression of IL-15Ra and downregulation of MICA/B. A, downregulation of MICA/B expression on melanoma
cell lines in vitro. Flow cytometry analysis of MICA/B expression at 48 hours after exposure to sorafenib at increasing concentrations gating on live MEL10
and MEL888 cells. FMO-control is indicated in thin black line. Representative overlays are shown. B, hematoxylin and eosin (H&E) staining of metastatic
melanoma lesions and immunofluorescence using anti-IL-15Ra antibodies. Nuclei are visualized with a DAPI (blue) staining, whereas melanoma
plasma membrane appears in red (staining with secondary anti-goat IgG Alexa Fluor 568 recognizing the anti-IL-15Ra antibody). Two representative
patients' paired lesions (pre- and posttherapy) are shown. Right, graph representative of 8 independent tumor lesions examined before and after
therapy, showing the percentage of positivity. C, RT-PCR determinations of the relative expression of the IL-15Ra gene in 20 paired metastatic
melanoma lesions before and after three cycles of therapy. (Continued on the following page.)
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at 3months (CRþPRþSD called hereafter "responders") and 37
progressive disease being referred to as "nonresponders"
according to the RECIST criteria (Table 1). Severe lymphopenia
was observed in both responders and nonresponders (Supple-
mentary Fig. S2A and S2B).
We phenotyped circulating lymphocytes in a longitudinal
study over 2 months in 63 patients included in this phase I/II
trial. All patients with metastatic melanoma showed a signif-
icant reduction of NKG2D expression in both CD8þ T and NK
cells at diagnosis compared with healthy volunteers (Fig. 1A).
Conversely, there was a higher proportion of CD4þ T cells
expressing NKG2D in all patients with metastatic melanoma
compared with healthy volunteers (Fig. 1A, right). These CD4þ
NKG2DþT cells differed from theCD4þNKG2DT-cell subset in
that they coexpressed low levels of CD8ab (Fig. 1B) and
exhibited an effector memory (TEM; CD45RA
CCR7) pheno-
type (Fig. 1C). Extensive phenotyping showed that about 20%of
CD4þNKG2Dþ T cells expressed the C-type lectin receptor
NKR-P1A (CD161) as described by others (29), but failed to
express other NK receptors (such as 2B4, KIR, NCR, and CD94/
NKG2A) in contrast to previously described CD4þNKG2Dþ T
cells (Fig. 1D; ref. 30). Finally, CD4þNKG2Dþ T cells did not
express the fractalkine receptor CX3CR1 associated with T-cell
trafficking into tumor beds (Fig. 1D).
Lymph node resection in high-grade melanoma allowed
us to examine the capacity of CD4þNKG2Dþ T cells to traffic
to tumor beds. Indeed, this subset represented up to 2% to
25% of the CD4þ tumor-infiltrating lymph node T cells (Met
lymph node), generally not enriched compared with blood or
nonmetastatic lymph node (non-Met lymph node; when
paired specimen were available; Fig. 2A), and expressed
higher levels of PD-1 (but similar levels of TIM-3) molecules
compared with NKG2D CD4þ T cells (Fig. 2B and C). Of
note, these Met lymph node contained about 73%  20% of
CD45 cells.
Altogether, the regulation of NKG2D expression in CD4þ
versus CD8þ or NK cells is uncoupled in patients with met-
astatic melanoma. The accumulation of CD4þCD8dim or CD4þ
NKG2Dþ T-cell subset in blood (and tumors) is frequently
observed in melanoma but can also be found in other malig-
nancies (Supplementary Fig. S3).
Th1 polarization of CD4þNKG2Dþ T cells upon
engagement of NKG2D and CD122
First, we analyzed the capacity of CD4þ T cells to secrete
cytokines after engagement of the T-cell receptor (TCR) and/or
NKG2D before therapy. A strong synergistic effect on the
production of IFN-g , IL-2, and TNF-awas observed when both
receptors were triggered (Fig. 3A) in responders as well as in
nonresponders (not shown). Importantly, upon TCR and
NKG2D triggering, this subset failed to produce IL-17 or IL-
10 (not shown). Intracellular staining revealed that most CD4þ
NKG2Dþ T cells produce both IFN-g and TNF-a (Fig. 3B).
Because IL-15 has been shown to be a key factor in arming an
NKG2D-dependent activation of TCRab CTLs in celiac disease
(31), we addressed whether purified CD4þNKG2Dþ T cells
could be activated by coengagement of NKG2D and/or CD122
(IL-2Rb common to both IL-2/IL-15 signaling) with a subop-
timal cross-linking of CD3molecules. Although CD4þNKG2D
T cells failed to release IFN-g upon receptor engagement, cell-
sorted CD4þNKG2Dþ T cells produced high levels of Th1
cytokines after a combined stimulation through TCR, CD122,
and NKG2D (Fig. 3C). To further characterize the functions of
these cells, we performed three additional assays (Supplemen-
tary Fig. S4). First, we incubated the NKG2Dþ or NKG2D cell
subset with soluble MICA (sMICA; expected to trigger NKG2D)
and rhIL-15 (expected to stimulate IL-2Rbg) in vitro in the
presence or absence of a TCR engagement. Interestingly,
sMICAþIL-15 could independently of TCR engagement syn-
ergistically induce IFN-g secretion in the CD4þNKG2Dþ T-cell
subset (as in NK cells) but not in CD4þNKG2D T cells
(Supplementary Fig. S4A). However, proliferation of either
NKG2Dþ or NKG2D CD4þ T cells could only be induced
after CD3 cross-linking (Supplementary Fig. S4B). In contrast
to their NKG2D counterparts, the CD4þNKG2Dþ effectors
were also able to recognize and kill melanoma cells (MEL10
cell line) after IL-15 priming (Supplementary Fig. S4C).
Sorafenib exposure did not enhance their cytotoxicity, which
might be explained by the reported direct inhibitory activity
of sorafenib on T-cell functions (32). Moreover, as shown
in Fig. 4, IL-15Ra expression was only weakly increased
(Fig. 4D) on the cell surface of MEL10 cells by sorafenib
treatment (Fig. 4E), which could explain why the addition of
IL-15 to engage CD122 was mandatory for the MEL10 cell line.
To follow up on this, we then switched to the melanoma cell
line MEL888, of which sorafenib had shown greater impact on
the expression of IL-15Ra both onmRNA levels and cell surface
(Fig. 4E and D), and tested the activation of CD4þNKG2Dþ T
cells without the addition of exogenous rhIL-15 in the presence
of sorafenib-treated or -untreated MEL888 cells. The result
showed that CD4þNKG2Dþ T cells could only secrete IFN-g in
the presence of sorafenib-treated MEL888 cells (Supplemen-
tary Fig. S4D).
Thus, CD4þNKG2Dþ T lymphocytes constituted an TEM
Th1-polarized T-cell subset capable of releasing cytokines
upon TCR engagement with a strong costimulatory activity
of the NKG2D receptor or upon coengagement of CD122 and
NKG2D receptors.
(Continued.) D, flow cytometry analyses of IL-15Ra expression on three melanoma cell lines after in vitro exposure to increasing dosing of sorafenib.
Ratio of mean fluorescence intensity (MFI) between FMO-control and specific stainings is shown after an overnight culture in control medium with DMSO,
sorafenib (with a dose response), and/or temozolomide (at 50 mmol/L, not shown, but no upregulation). Each determination was performed
twice with similar results. E, fold change RT-PCR of IL-15Ra gene expression after an 18-hour incubation of three cell lines with imatinib (1 mmol/L),
vemurafenib (10mmol/L), or sorafenib (10mmol/L) at doses triggering significant cell deathor proliferationarrest. DMSOwasusedascontrol. F, IL-15Raprotein
expression, monitored on CD14þ PBMCs, in nonresponding (NR; n ¼ 11; left) and responding (R; n ¼ 12; right) patients. For each patient, specific IL-15Ra
staining and FMO control were performed at baseline (C0) and after two cycles (C2) of sorafenib/temozolomide. The dots represent the ratio of the MFI of the
specific IL-15Ra signal to the MFI of the FMO control for each patient at C0 and C2. , P < 0.05; ns, not significant using Wilcoxon signed-rank test.
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Regulation of IL-15Ra expression by sorafenib in tumor
beds
We analyzed how sorafenib or temozolomide could mod-
ulate the expression of the ligands for these receptors in vitro
and in vivo. Lymph node–residing melanoma was reported
to express low levels of NKGD ligands (33). We analyzed
sixteen "paired" but independent tumors (mostly from sub-
cutaneous lesions), before and after three cycles of therapy
by immunohistochemistry of paraffin-embedded melanoma.
First, anti-CD3, -CD4, and -CD8 antibody stainings revealed
abundant infiltrates that were not significantly altered by
therapy (Table 2 and Supplementary Fig. S5). The SR99
antibody recognizing MICA/B revealed that the intensity of
the staining seemed moderate to strong on plasma mem-
brane and in the cytosol in all specimens regardless of the
location (Supplementary Fig. S5 and Table 2). Of note, no
staining was observed in the epidermal or mesenchymal
cells of normal skin adjacent to the melanoma (not shown).
The expression of MICA/B proteins was maintained by the
therapy in tissue sections (Table 2) although sorafenib could,
with increasing concentrations, downregulate MICA expres-
sion on melanoma cell lines in vitro, especially on MEL888
cells (Fig. 4A). Note that treating the MEL888 cells with 10
mmol/L sorafenib for 24 hours led to the release of sMICA/B
in the supernatant (not shown).
We also monitored the IL-15Ra expression on tumor
cells. Immunofluorescence analyses of paired melanoma
pre- and posttherapy using anti-IL-15Ra–specific antibo-
dies revealed that in most cases (7 of 8 patients), therapy
increased cell-surface expression of IL-15Ra on tumor cells
(Fig. 4B). RT-PCR analyses of 20 tumor biopsies compared
the relative expression of the IL-15Ra gene pre- versus
posttherapy and confirmed, in 4 cases, the upregulation of
transcription or a strong and stable basal expression in 2
cases (Fig. 4C). Corroborating these data, sorafenib induced
cell-surface expression of IL-15Ra and enhanced transcrip-
tion of IL-15Ra in melanoma lines in vitro (Fig. 4D). Note
that temozolomide was not able to induce IL-15Ra expres-
sion in vitro and did not inhibit IL-15Ra expression induced
by sorafenib (not shown). Interestingly, B-RAF or c-KIT
inhibitors (vemurafenib or imatinib) failed to modulate
IL-15Ra in melanoma cell lines in vitro (Fig. 4E). Monitoring
of IL-15Ra on peripheral blood CD14þ cells at baseline and
after two cycles of treatment revealed an upregulation
preferentially in responding patients (Fig. 4F), and in
patients with longer OS (over the median time of survival,
224 days; P ¼ 0.03 with Wilcoxon signed-rank test; data
not shown).
Microarray analysis was performed on 20 paired biopsies
before (day 0) and after treatment (day 21) from 20 patients by
establishing the log ratio (day 21/day 0) to identify genes that
could be modified by the treatment regardless of the clinical
response. This analysis revealed a cluster of genes among
which IL-15, STAT5, and STAT1 appeared first as upregulated
after treatment (Supplementary Fig. S6). Because of the limited
number of samples and the absence of a validation set, it was
impossible to perform relevant analysis to distinguish respon-
ders from nonresponding patients.
To conclude, sorafenib alone or combined with temozolo-
midemay inducemembrane expression of IL-15Ra in vitro and
in vivo in patients with melanoma.
Increase of CD4þNKG2Dþ T cells associated with OS
Given the sorafenib-induced accumulation of CD4þ
NKG2Dþ Th1 cells and IL-15Ra expression in melanoma
lesions, we hypothesized that this subset could influence
therapeutic outcome. We analyzed potential correlations
between the frequencies of CD4þNKG2Dþ T, CD8þNKG2Dþ
T cells, and CD56þNKG2Dþ NK cells at various time points
with the clinical response evaluated at 2 months and OS. None
of these parameters was associated with clinical response at
any time points (Supplementary Fig. S2C and data not shown).
However, lymphopenia at baseline influenced OS. Considering
that median survival of the whole cohort is 227 days, patients
Table 2. Semiquantitative assessment of CD3, CD4, CD8, and MICA infiltrates by IHC
Before therapyb After therapyb
Patientsa Clinical response CD3 CD4 CD8 MICA/B CD3 CD4 CD8 MICA/B
13 R þþ þ/ þþ þþ þþ þ þþ þ
26 R    þþ þ   þ
34 NR þ   þ þ   þ
38 NR þ   þþ þ   þþ
40 R þ þ þ þ þ þ þ þ
41 R þþ þ þ þ þþ þ þ þ
47 NR þ   þ þ   þ
48 NR þ  þþ þþ þ  þ þþ
49 NR þ  þþ þ þþ  þþ þ
Abbreviations: R, responder; NR, nonresponder.
aInclusion number.
bStaining estimations assessed by two independent pathologists: , no staining; þ/, weak; þ, intermediate; þþ, strong.
Romero et al.
Cancer Res; 74(1) January 1, 2014 Cancer Research76
on January 23, 2020. © 2014 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 6, 2013; DOI: 10.1158/0008-5472.CAN-13-1186 
with prolonged survival (>227 days) exhibited higher lympho-
cyte counts at baseline compared with rapidly progressive
patients (Fig. 5A). Importantly, the increase of circulating
CD4þNKG2Dþ T cells at two cycles of therapy was associated
with prolonged survival, whereas the parallel decrease of CD8þ
NKG2Dþ or CD56þNKG2Dþ NK cells was not (Fig. 5B and C
and Supplementary Fig. S2D). The elevation of CD4þNKG2Dþ
T-cell subset observed post-sorafenib (combined with temo-
zolomide) was not apparent after miscellaneous lines of con-
ventional therapies (including DTIC, fotemustine, isolated
limb perfusion, vaccines) where long-term or short-term sur-
vivors had no more than 2.5% to 3% of CD4þNKG2Dþ T cells
(Fig. 5D). Altogether, it is tempting to speculate that the
accumulation of CD4þNKG2Dþ Th1 cells may be regulated
by a therapy facilitating the exposure of IL-15Ra on tumor cells
and/or circulating monocytes.
Discussion
Here, we report the first demonstration that sorafenib
(combined with temozolomide) could (i) increase the pro-
portion of a rare subset of TEM CD4
þNKG2Dþ Th1 cells, and
(ii) induce the upregulation of IL-15Ra on monocytes and/or
in tumor sections. NKG2D ligands along with the therapeu-
tic induction of IL-15Ra expression on the plasma mem-
brane of tumor cells (and/or monocytes) could restore/favor
the activation of tumor-infiltrating effector lymphocytes. We
show that these molecules are either detectable at baseline
(MICA expression) or induced by sorafenib (IL-15Ra) in
metastatic melanoma where a subpopulation of rare
CD4þ T cells expressing NKG2D is abnormally represented
(compared with healthy volunteers). This subset can be
induced to proliferate after engaging TCR and NKG2D
receptors and to release Th1 cytokines after engaging CD122
and NKG2D receptors.
Several subsets of CD4þNKG2Dþ T cells have been
described. First, in patients with cancer, tumor expression and
shedding of sMICA/B ligand of NKG2D drove the proliferation
of a CD4þNKG2DþT cell population that produced IL-10, TGF-
b, and FasL (34, 35). The expansion of these cells inhibited
bystander CD8þ and CD4þ T-cell proliferation ex vivo. The
same autoreactive T-cell subset was inversely correlated with
disease activity in autoimmune diseases (such as juvenile-
onset systemic lupus erythematosus). In this report, sMIC
serum levelswere also inversely correlatedwith disease activity
(36). Second, in contrast to this "regulatory" phenotype, a
"proinflammatory" and cytolytic CD4þNKG2Dþ T-cell subtype
has been described in autoinflammatory diseases such as
Wegener's granulomatosis (37, 38), rheumatoid arthritis (39),
and Crohn's disease (40). In most of these reports, CD4þ
NKG2Dþ T cells harbor an effector-memory phenotype and
express many other NK-cell activating receptors (such as 2B4,
DNAM-1, and CRACC) likely contributing to pathogenesis.
Indeed, coligation of 2B4 in combination with DNAM-1 or
NKG2D enhanced CD4þCD28T-cell degranulation and IFN-g
secretion engaged through suboptimal TCR triggering (30).
Those TEM CD4
þNKG2Dþ T cells were found in Wegener
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Figure 5. CD4þNKG2Dþ T cells are
increased posttherapy in patients
experiencing prolonged OS. Total
lymphocyte counts (A), proportions
of CD4þNKG2Dþ (B), or CD8þ
NKG2Dþ (C) T cells at C0, C1, and
C2 were analyzed according to a
stratification of patients based on
their OS (<227 or >227 days, the
median survival of the whole
cohort). D, proportions of CD4þ
NKG2Dþ T cells after several
treatment cycles in 18 patientswith
metastatic melanoma treated with
conventional therapies (including
DTIC, fotemustine, isolated limb
perfusion, and vaccines) stratified
by their OS (<385 or >385 days, the
median survival of this cohort). The
frequency variations during
treatment were analyzed using
the paired Student t test and
subgroup comparisons were
analyzed by the Student
t test. (, P < 0.05; , P < 0.01;
, P < 0.001; ns, not significant).
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granulomata in close association with MICþ and IL-15þ cells
and CD208 dendritic cells (37). It is known that IL-15 upregu-
lates NKG2D expression on T cells and MIC expression on
inflamed tissues and drives TEM differentiation and prolifer-
ation, culminating in exacerbation of autoimmune diseases
(39, 41). Meresse and colleagues elegantly demonstrated in
CD8þ T cells that dysregulated IL-15 expression promotes the
NKG2D/DAP10 signaling pathway leading to CTL cytotoxic
activity independently of the engagement of the TCR, trans-
forming CTL into "LAK-like"LAK-like cells (31). As for CD8þ T
cells, lamina propria CD4þ T cells from Crohn's disease
expressing NKG2D, Th1 cytokines, and perforin were func-
tionally active through MICA/NKG2D interactions (40). Third,
an increased frequency of double-positive CD4þCD8þab T
cells (DP cells) was reported in Hodgkin lymphoma, human
breast cancer pleural effusions (29), and in melanoma (42).
However, these DP cells express high levels of CD8ab, low
levels of CD4, and produce Th2 cytokines upon HLA class I–
restricted recognition of tumor cells and normal cells, sug-
gesting that they are "regulatory" CD8þ T cells specific for self-
antigens. Fourth, Maccalli and colleagues characterized CD4
and CD8 T-cell clones from melanoma lesions for their
dependency on TCR versus NKG2D in the recognition pat-
terns of melanoma cells. Very few T-cell clones were CD4þ
NKG2Dþ and they recognized tumor cells mainly in a MHC
class II–dependent fashion. Moreover, MICA/B expression
was rather low in lymph node melanoma, whereas ULBP-2
was more prominent and functionally relevant (33). In our
report, CD4þNKG2Dþ T cells shared biologic and functional
features with proinflammatory CD4þNKG2Dþ T cells. Indeed,
the CD4þNKG2Dþ T-cell subset that we observed in these
patients with metastatic melanoma were enriched with TEM
cells, expressed low levels of CD8ab and high levels of CD4,
secreted Th1 cytokines, and could proliferate upon subopti-
mal TCR triggering along with NKG2D and/or CD122 engage-
ment. The major difference is the lack of NK cell receptor
expression. Only NKG2D and CD161 (29, 41–44) were
expressed in this cohort CD4þNKG2Dþ T cells.
The proof-of-principle that CD4þ T cells can be thera-
peutically harnessed against metastatic melanoma has been
brought up by Hunder and colleagues, where they used IL-2
and IL-7 to differentiate tumor-specific CD4þ T cells (43).
Others have found that na€ve CD4þ T cells after adoptive T-
cell transfer can be cytotoxic and highly contribute to tumor
rejection (45). Such efficient T-cell response strongly relied
upon lymphopenia and common g chain (such as IL-15).
Furthermore, an appropriate dendritic cell or monocyte/
CD4þ T-cell cross-talk will lead to both IL-15–driven IL-12
production by dendritic cell, and enhanced proliferation and
polarization of Th1 cells (46). Cytokine/antibody immune
complexes to IL-15 or IL-2 or IL-7 may mimic the effects of
lymphopenia required for such an efficient triggering of
na€ve CD4þ T cells. Therefore, it is likely that the combina-
tion of temozolomide and sorafenib, through prolonged
lymphopenia, may foster an environment for the proper
polarization and expansion of effector CD4þ T cells in a
tumor milieu providing the right costimulatory molecules
(IL-15Ra and MICA/B). Supporting this premise, our tran-
scriptional profiling indicates that the IL-15/IL-15Ra signal-
ing pathway and Th1 signatures are induced in lesions
posttherapy (Supplementary Fig. S6).
In the absence of IL-15Ra induction, however, many strat-
egies could be envisaged to compensate these patients. Cis- or
trans-stimulating IL-2Rbg through stabilized IL-15–based
approaches have been tested in preclinicalmodels (47). Indeed,
IL-15/IL-15Ra-Fc, IL-15/IL-15Ra fusion proteins, IL-15 fused
to the human antibody fragment (scFv) specific of a tumor
antigen or the tumor stromal fibroblast activation protein, IL-
15 gene therapy (such as the hydrodynamic injection of plas-
mids encoding IL-15 or IL-15 engineered oncolytic viruses)
have all been reported to be efficient against mouse tumors.
Our data suggest that a subset of CD4þ T cells (expressing
NKG2D) becomes biologically significant in that they may be
engaged by IL-15Ra and MICA/B expressed on tumor cells
and/or monocytes (either through sorafenib or spontaneously,
respectively) to secrete high levels of Th1 cytokines.We cannot
exclude that other NKG2Dþ-expressing effectors could be
implicated as we could also monitor CD8þ T cells infiltra-
ting tumors. However, it seems that only CD4þNKG2Dþ T cells
could be augmented after two cycles of therapy, which turned
out to be clinically relevant and associated with longer OS.
In conclusion, our data suggest that CD4þNKG2Dþ T cells
could be tuned functionally by induction of IL-15Ra. This
observation could have some clinical impact, as compounds
inducing or mimicking IL-15 transpresentation are currently
under development for the treatment of cancer.
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